MedPath

Eplivanserin

Generic Name
Eplivanserin
Drug Type
Small Molecule
Chemical Formula
C19H21FN2O2
CAS Number
130579-75-8
Unique Ingredient Identifier
3CO94WO6DJ
Background

Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others.

Clinical Trials
Related News

Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia

Phase 1
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
First Posted Date
2009-06-04
Last Posted Date
2010-11-30
Lead Sponsor
Sanofi
Target Recruit Count
41
Registration Number
NCT00913614
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties

Phase 3
Completed
Conditions
Primary Insomnia
Interventions
Drug: Placebo
First Posted Date
2008-12-09
Last Posted Date
2016-03-07
Lead Sponsor
Sanofi
Target Recruit Count
637
Registration Number
NCT00805350
Locations
๐Ÿ‡ต๐Ÿ‡ฑ

Sanofi-Aventis Administrative Office, Warszawa, Poland

Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
First Posted Date
2008-05-19
Last Posted Date
2010-11-30
Lead Sponsor
Sanofi
Target Recruit Count
283
Registration Number
NCT00679900
Locations
๐Ÿ‡ช๐Ÿ‡ธ

Sanofi-Aventis Administrative Office, Barcelona, Spain

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Phase 2
Completed
Conditions
Fibromyalgia
Sleep
Chronic Pain
Interventions
Drug: placebo
First Posted Date
2006-04-12
Last Posted Date
2010-11-30
Lead Sponsor
Sanofi
Target Recruit Count
205
Registration Number
NCT00313885
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Wichita Clinic PA, Wichita, Kansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Renstar Medical Research, Ocala, Florida, United States

and more 9 locations

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Insomnia
Interventions
Drug: placebo
First Posted Date
2006-03-29
Last Posted Date
2010-11-30
Lead Sponsor
Sanofi
Target Recruit Count
608
Registration Number
NCT00308503
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

Sanofi-Aventis, Laval, Canada

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Insomnia
Interventions
Drug: placebo
First Posted Date
2005-11-15
Last Posted Date
2010-11-30
Lead Sponsor
Sanofi
Target Recruit Count
1155
Registration Number
NCT00253903
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Sanofi-Aventis Administrative Office, Guildford, United Kingdom

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Insomnia
Interventions
Drug: placebo
First Posted Date
2005-11-15
Last Posted Date
2016-03-01
Lead Sponsor
Sanofi
Target Recruit Count
967
Registration Number
NCT00253968
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Sanofi-Aventis Administrative Office, Guildford, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy